Interleukin 12 ( IL -12 ) is a cytokine that promotes an antitumor Th1 -type pattern of differentiation in mature naïve T cells. Despite its therapeutic success in multiple animal models of cancer, the utility of systemically administered recombinant cytokine has been limited by its toxicity. This has encouraged the development of local IL -12 delivery systems through gene transfer. To determine the effect of local adenoviral delivery of IL -12 on glioma immunogenicity, mice bearing GL -26 gliomas in the right corpus striatum were treated with direct intratumoral administration of AdmIL -12, AdLacZ, or normal saline. Survival was significantly prolonged in AdmIL -12 -treated animals and immunohistochemistry demonstrated robust CD4 + and CD8 + T -cell infiltration in these mice compared to the two control groups. Glioma -infiltrating T lymphocytes from mice that received AdmIL -12 also demonstrated relatively increased, albeit statistically nonsignificant tumor killing. Based on IL -12's known ability to enhance Th1 -type cytotoxic antitumor immune responses, we postulate our findings to be a result of localized induction of tumor immunity.
I nterleukin 12 ( IL -12 ), a powerful immunostimulatory cytokine, has received considerable attention as an antitumor agent. Systemic administration of recombinant IL-12 in a variety of rodent tumor models including carcinomas, sarcomas, melanomas, and lymphomas has been shown to significantly impair tumor growth and enhance survival. 1 -3 In certain cases, complete eradication of tumor has also been observed. 4 The tumoricidal efficacy of IL -12 stems from its promotion of a strong antitumor cytotoxic immune response.
5 CD4 + T cells have been shown to polarize toward two separate states of activity, namely T helper type 1 (Th1 ) and T helper type 2 ( Th2 ), with the differentiation based chiefly on the effector cytokines produced and their resultant functions. 6, 7 The Th1 response, an important promoter of antitumor cytotoxicity, is characterized by the dominant production of interferon gamma and IL-2. 8 In contrast, Th2 activity is associated with the secretion of IL -4, which plays a role in the enhancement of humoral immunity. Glioma-infiltrating T lymphocytes have been shown to be primarily in a state of Th2 activation, 9 suggesting the possibility of a suboptimal cytotoxic tumoricidal immune response against these tumors. IL -12 facilitates the development of interferon gamma secreting tumor-specific Th1 T cells and tumorinfiltrating lymphocytes (TILs ), thereby enhancing tumoricidal cytotoxicity. 4 It is postulated that the significant results seen in animal models of cancer treated with IL -12 are a result of such enhancement in Th1 activity.
In patients with cancer, therapeutic success using systemically administered recombinant IL -12 has been limited owing to its severe toxicity. 10 As a result, strategies aimed at localized delivery of cytokine have received increasing attention. Recently, the advantages of intratumoral paracrine delivery of IL -12 using gene therapy have been documented. 11, 12 With particular reference to brain tumors, encouraging results have also been obtained with intratumoral cytokine infusion, 13 ex vivo engineered IL -12-secreting tumor cells, 14 and herpes simplex -mediated IL-12 gene therapy 15 in rodent brain tumor models. With the aim of further investigating this therapeutic strategy in the setting of brain tumor therapy, we describe the use of a replicationdeficient adenoviral vector encoding IL -12 for the treatment of a murine glioma model. We demonstrate that intratumoral delivery of AdmIL-12 reduced tumor volume and prolonged survival in a syngeneic murine glioma model. These biologic effects were mediated by the induction of significant immune cell cytotoxicity as demonstrated by long -lasting immunity to tumor, intracranial infiltration of CD4 + and CD8 + T cells, and a demonstrable trend of increased, albeit statistically nonsignificant, cytotoxicity of TILs against GL -26 tumor cell targets.
Materials and methods

Plasmid construction and adenovirus rescue
The construction of recombinant adenoviral vectors bearing the genes for IL -12 has been reported previously. 16 Briefly, plasmids expressing the p35 and p40 subunits of IL -12 were used to transform Escherichia coli DH5 by electroporation. The murine p35 and p40 cDNAs were obtained from the plasmids pVL21L12p35 and pMEIL12p40#4, respectively. Recombinant adenoviruses were rescued and propagated using the 293 cell line. The AdmIL-12 virus was a gift of Dr Frank Graham. A replication deficient adenovirus with the LacZ gene was constructed as described by Schaak et al. 17 This second virus served as a negative control vector in our experiments.
Cell culture
The 293 cell line ( adenoviral E1 -transformed human embryonic kidney cells ) was maintained in Dulbecco's modified eagle's medium ( DMEM ) supplemented with 10% fetal calf serum ( FCS; Gibco BRL, Gaithersburg, MD ). The GL -26 cells ( murine glioma ) were grown in DMEM plus 10% FCS. All cell culture media were supplemented with 2 mM L -glutamine, 100 g/mL penicillin, and 100 U / mL streptomycin.
Secretion of murine IL -12 by AdmIL12 -infected glioma cells
One million GL -26 glioma cells were infected with AdmIL -12 at different multiplicities of infection (MOIs ) in a total volume of 0.5 mL. After 2 hours, the viral supernatant was replaced with culture medium. Forty -eight hours later, the supernatant was collected and tested for mIL -12 by enzyme -linked immunosorbent assay ( ELISA; Pharmingen, San Diego, CA ).
In situ infection of intracranial glioma with AdmIL -12
Six -to eight -week -old syngeneic C57BL / 6 mice were obtained ( Charles River, Wilmington, MA ). Following intraperitoneal anesthesia using ketamine (30 mg /kg) and xylazine (30 mg /kg ), the right striatum was stereotactically injected with 10 4 GL -26 glioma cells in 2.5 L of 1.2% methylcellulose. At day 4 post implantation, animals received treatments of 5Â10 8 plaque -forming units (pfu ) of recombinant adenoviral vectors ( AdLacZ and AdmIL -12 ) in 2.5 L of serum -free medium, injected directly into the established tumor using the previously created burr hole and stereotactic coordinates. Animals were handled and cared for in strict accordance with the Animal Care and Use Committee guidelines in force at Cedars Sinai Medical Center.
Peripheral vaccination with IL -12 -secreting GL -26 glioma cells
With the aim of investigating the effect of peripheral vaccination with IL -12-secreting cells on enhancing survival in GL -26 glioma -bearing mice, C57Bl/ 6 mice were stereotactically implanted with 10 4 GL -26 glioma cells each. Five days following this implantation, the mice were divided into three groups of 9 -11 mice each and were vaccinated subcutaneously with 5Â10 6 GL -26 cells infected with either AdmIL -12 or AdLacZ at an MOI of 1000, or mock infected with saline. Cells were irradiated with 3000 rad to induce growth arrest before vaccination. Animals in each group were followed for survival.
Cytotoxic T -lymphocyte ( CTL ) assay
Assessment of CTL activity was performed using a DNA fragmentation assay (JAM test ) as described by Matzinger. 18 Three weeks after tumor implantation, intracranial tumors from five animals from each of the treatment groups were harvested. Tumor tissue was pooled for each group separately, then physically disrupted and lymphocytes isolated from tumor tissue by ficoll gradient centrifugation. In vitro stimulation with 20 U per well of recombinant IL -2 (Pharmingen ) was performed for 5 days in 24 -well plates, each well containing 1Â10
4 GL -26 cells that had received 15,000 rad ( 15 Gy ) of radiation and 1Â10 6 nonirradiated TILs. RPMI media containing 5% FCS was used ( Gibco BRL ). Effector cells were co incubated with 3 Hthymidine (20 Ci for 1Â10 6 cells in 1.5 mL of media) labeled targeT-cells for 6 days at 378C in different effector to targeT-cell ratios. After incubation, cells were harvested and DNA fragmentation assessed using a Micro Beta Trilux beta counter ( EG & G Wallac, Turku, Finland ). This experimental procedure was repeated three times. The percentage of specific cytolysis was calculated as [( spontaneous release À experimental release)/( spontaneous release À maximum release)] Â100.
Long -term survival analysis
Animals harboring GL -26 tumors were divided into three groups and treated as described with AdmIL12, AdLacZ, or normal saline. Animals were monitored daily and euthanized when they developed terminal neurologic symptoms and the results analyzed statistically using a Wilcoxon test. Four months after the original implantation, surviving mice that did not succumb to the initial tumor inoculation were rechallenged intracranially with 10 4 GL -26 cells administered in the same manner described earlier. At this same time, six additional naïve mice were also implanted intracranially with the same number of GL -26 cells to serve as controls for the surviving rechallenged mice. These mice were monitored for up to 3 months, after which they were sacrificed and their brains examined histologically.
Determination of tumor size
Three weeks following treatment interventions, animals were sacrificed and their brains harvested and frozen in dry ice. Using a cryostat, the brains were then cut into 12 -m coronal sections and transferred onto glass slides. Tumor diameter was measured on different slides under a light microscope using a precision caliper at a magnifi-cation of 40Â. Tumor volume was calculated using the formula: Volume (mm 3 )= LÂS 2 , where L and S are the largest and smallest diameters of the largest tumor section visualized.
Immunohistochemistry
Brain tissue for histological examination was obtained after animals were euthanized by CO 2 asphyxiation. Harvested brains were frozen in dry ice and subsequently sectioned in a coronal plane in 12-m slices, which were then transferred to slides and allowed to air dry overnight. Fixation was performed with 4% paraformaldehyde followed by overnight incubation with biotinylated rat anti -mouse CD4 (clone H129.19) or CD8 ( clone 53 -6.7 ) mAb (both diluted 200Â ) ( Pharmingen ) at 48C. Next, the sections were washed with phosphate buffered saline and incubated with Vectastain ABC reagent conjugated with peroxidase ( Vector Laboratories, Burlingame, CA ) for 30 minutes at room temperature. Antibody binding was visualized with diamino benzidine tetrahydrochloride.
Quantification of CD4 + and CD8 + TILs
Two separate stained histological sections from two different animals were used for quantification of CD4 + and CD8 + tumor-infiltrating cells in each intracranial treatment group. For each section, positive cells from three random fields, measuring 0.196 mm 2 each, were counted under a light microscope by two investigators blinded to animal history. Values from each investigator for each field were averaged.
Results
In vitro infection of GL -26 cells using AdmIL -12
To determine whether infection of glioma cells with AdmIL -12 produced biologically relevant secretion of IL -12, murine GL -26 glioma cells were infected with AdmIL -12 at different MOIs. Using an MOI of 1000 pfu /cell, the cells secreted 12.5 ng /mL per 10 6 cells per 24 hours, thereby confirming the secretion of murine IL -12 by AdmIL -12 -infected glioma cells (data not shown).
Glioma -bearing mice treated with AdmIL -12 demonstrate enhanced survival C57Bl/6 mice were divided into three treatment groups of 10-12 animals each. Each group received intracranial implantations of GL -26 tumors followed 4 days later by intratumoral inoculations of AdmIL-12, AdLacZ, or normal saline. Of the 12 animals that received IL -12 therapy, 6 remained surviving 60 days after the date of viral inoculation. In contrast, only 1 animal of 10 in each of the control groups was able to survive for the same duration. The survival advantage conferred by AdmIL -12 therapy was highly significant when compared to either of the control groups ( Wilcoxon test; P < .001) (Fig 1A ) . In contrast mice vaccinated peripherally with AdmIL -12 -infected GL -26 cells did not demonstrate any significant enhancement in survival when compared to controls that received peripheral immunization with AdLacZ transduced or mock -infected GL -26 cells ( Fig 1B ) .
Effect of AdmIL -12 gene therapy on in vivo tumor growth
We sought to determine whether the prolongation of survival seen in the group treated intracranially with AdmIL-12 was due to inhibition of tumor growth. Three weeks following intracranial inoculation of virus, mice were sacrificed and tumor volumes determined. Differences in tumor volume between the three treatment groups are illustrated in Figure 2 . The mean tumor volume in the AdmIL-12 -treated mice was 11.2 mm 3 (SE= ±2.3 mm 3 ) compared to 65.6 (SE = ± 7.4 mm 3 ) in the saline-treated Cancer Gene Therapy group, with this difference being highly significant ( ANOVA t test; P <.001 ).
IL-12 gene therapy confers long -lasting protection
Intratumoral administration of AdmIL -12 prolonged survival by inhibiting tumor growth. We sought to determine whether this inhibition of tumor growth was due to an immune response. Three AdmIL -12-treated animals that demonstrated long -term survival were rechallenged with a second intracranial implantation of 5Â10 4 GL -26 cells. All of these animals survived for 4 months after this second procedure at which point they were sacrificed and their brains harvested and analyzed. No evidence of tumor was found, indicating that these animals had rejected the second tumor challenge. Six naïve animals were implanted at the same time as the surviving AdmIL -12 mice were rechallenged, and all six animals died within 60 days of tumor inoculation.
Tumor sections from AdmIL -12 -treated mice demonstrate increased CD4 + and CD8 + T -cell infiltration
To visualize tumor T-cell infiltration, immunohistochemistry was performed on frozen brain sections from all three intracranially treated groups 3 weeks after intracranial viral inoculation. T-cell content for both CD4 + and CD8 + cells was substantially increased in sections derived from AdmIL-12 -treated animals ( Fig 3 ) . All of these sections demonstrated visibly smaller tumors with significantly higher immune cell infiltration than controls. Tumor-infiltrating CD4 + and CD8 + cells were quantified as described in Materials and methods. Immune cell infiltration was significantly higher in AdmIL -12 inoculated animals compared to AdLacZ -treated controls (Student's t test; P < .01 ) ( Fig 4 ) .
TILs demonstrate increased cytotoxicity against GL -26 murine glioma cells
We then focused on assessing whether these intracranial T cells had cytotoxic activity against glioma cells. TILs were tested against a GL -26 targeT-cell line (Fig 5) . Our results indicate that populations of intracranial T lymphocytes in mice treated with AdmIL -12 exhibited relatively increased cytotoxicity compared to control animals treated with AdLacZ. This difference was not statistically significant when subjected to a Student's t test ( P >.05 ).
Discussion
The role of IL-12 in experimental cancer therapy has been extensively investigated. 1,2 The use of IL -12 in multiple rodent tumor models has consistently demonstrated its tumoricidal potency, and in certain cases complete regression of existing tumors has also been observed. 4 The majority of work to date has focused on systemically administered recombinant IL -12. Although this remains strikingly effective in rodent models, often demonstrating complete tumor eradication, it is associated with signs of toxicity including ascites, dry mucus membranes, lack of grooming, hypophagia, and occasional death. 11 Fatal toxicity in a phase II human clinical trial utilizing systemic administration of recombinant IL-12 has also been reported. 10 For these reasons, systems focusing on local delivery of the cytokine to tumor tissue have gained popularity. IL -12 gene therapy models of murine metastatic colon carcinoma 19 and bladder carcinoma 11 have demonstrated significant enhancements in survival similar to those seen in systemic IL -12 immunotherapy.
The use of IL-12 in the treatment of intracranial malignancies has also been investigated. Kishima et al, 20 Joki et al, 21 and Kikuchi et al 22 established significantly improved survival in murine brain tumor models treated with systemically administered recombinant IL -12. Systemic IL-12 therapy was combined with either IL -2-secreting 22 or B7 -1-and ICAM -1-expressing 21 tumor cells with the aim of enhancing intratumoral antigen presentation. One of these studies also addressed local intracranial administration of recombinant IL -12 using five daily intrathecal doses. 20 Minimal regression of tumor growth was seen with locally administered cytokine. This was likely a function of the extremely short in vivo half -life of recombinant IL -12 and the resultant inadequacy of the intrathecal dosing. Another study investigated the role of local intracranial IL -12 infusion in a rat glioma model, again combined with subcutaneous irradiated tumor vaccination to enhance antigen presentation. 13 Significant prolongation of survival was also demonstrated in this study. In contrast to the intrathecal IL-12 infusion study, Jean et al 13 were able to demonstrate significant tumor regression using local intracranial cytokine delivery. This was likely due to their use of a continuous infusion system, which maintained intratumoral therapeutic levels of IL-12 for the duration of their study. Of significance is the failure of all these studies to demonstrate significant enhancements in animal survival or CTL responses using localized IL -12 delivery in the absence of adjuvant cytokine or vaccination therapy. The fact that two of the tumor models utilize pre -engineered tumor cell lines to enhance antigen presentation 21, 22 and that one uses cumbersome infusion methodology, 13 detracts from their clinical applicability and renders them impractical as templates for clinical translation. Parker et al 15 recently described the use of a neuroattenuated herpes simplex virus expressing IL -12 for the treatment of a murine neuroblastoma model. This study was able to demonstrate an increased tumor lymphocytic infiltrate and improvement in survival following herpes -mediated IL-12 gene therapy. The recently described use of ex vivo engineered IL -12-secreting 9L glioma cells in a rat model 14 was significant in establishing a basis for in situ IL -12 production in hindering tumor establishment and growth. Our study is, however, the first instance where IL -12 gene transfer has been used in the setting of established brain tumors, and is therefore of greater clinical relevance. In addition, we have been able to forward evidence that in situ IL-12 secretion may effect increased tumor-specific CTL activity in TILs. The lack of statistical significance in this increased CTL activity implies that our findings are, however, not entirely conclusive.
We have for the first time demonstrated a significant role for replication deficient adenoviral -mediated intratumoral IL -12 gene transfer in glioma immunotherapy. We have established significant prolongation in survival using local cytokine delivery alone without the use of adjuvant vaccination or cytokine therapy. Our methodology circumvents the risks of systemic toxicity and at the same time firmly establishes that local delivery of IL -12 to murine gliomas using gene transfer significantly enhances lymphocytic infiltration and may display a trend toward increased intracranial tumor-directed T-cell cytotoxicity. In contrast, peripheral vaccination with IL -12 -infected GL -26 cells did not confer a survival advantage when compared to intracranially inoculated animals. These findings would suggest that in the setting of brain tumors, peripheral vaccination confers limited antitumor effects compared to direct transfer of IL -12 to the tumor. We previously demonstrated the potent antitumor effect of IL -2 when secreted intracranially. Peripheral vaccination with IL -2 -secreting cells, although protective against peripheral challenge, was not protective against intracranial challenge. 23 This effect is in contrast to granulocytemacrophage colony -stimulating factor ( GM -CSF ), which is effective as a peripheral vaccine but ineffective when secreted intracranially in glioma and metastatic tumor models. 24, 25 Th1 activation by IL -12 and T-cell stimulation by IL -2, in the setting of the central nervous system ( CNS ), demonstrate potent induction of cytotoxicity only when secreted in situ. These findings suggest that T-cell populations activated in the periphery by IL-2 or IL -12 may not adequately access the CNS. Intratumoral expression of IL -12 serves to directly activate tumor-infiltrating immune cells. 26 Such localized immunotherapy may prove to be of significant advantage when compared to peripheral vaccination strategies, considering the inherent immune privileged status of the CNS, which hinders peripheral cytotoxic immune cells from trafficking into intracranial gliomas. IL-12 enhances the capacity of T cells to migrate into tumors thereby facilitating their infiltrative activity. 27 In our study, intracranial delivery and expression of IL -12 induced robust CD4 + and CD8 + T-cell tumor infiltration. These T cells recognized and were able to kill GL -26 tumor cells as demonstrated by a CTL assay of TILs.
Localized IL -12 gene transfer also conferred long -lasting immunity against tumor rechallenge. All mice that were tumor free for 3 months following initial tumor implantation resisted a second challenge with the same tumor cell line. This demonstrates that mice, which rejected their initially implanted tumors following IL -12 gene therapy, develop long -term tumor-specific immunity. Th1 activity is necessary for the effective transition of CD8 + tumor-specific cytotoxic T cells to memory cells. 28 Increased cytotoxic activity of TILs and evidence of T-cell memory serve as further evidence that we were able to achieve an enhancement in local Th1 activity using this IL-12 gene transfer strategy.
In the gene transfer model described by Parker et al, 15 a significant contribution to the demonstrated survival advantage is conferred as a result of active viral oncolysis by the recombinant herpes vector. We, however, demonstrate the effect of IL -12 gene transfer alone. In addition, we postulate that all of our demonstrated effects may result from an IL -12 -induced local intratumoral Th1 ''switch,'' enabling effective antitumor cell -mediated immunity. At the same time, our results indicate that T-cell cytotoxicity may be enhanced intracranially. We demonstrate that AdmIL -12 therapy improves glioma outcome. The suppression of a Th1 response may contribute to the ineffectiveness of endogenous antitumor immunity in glioma, and intracranial IL -12 expression may overcome this local Th1 suppression.
